Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

The company’s Innovative Medicine unit is showing a growth trend, driven by existing products like Darzalex, Tremfya and Erleada and continued uptake of new launches, including Spravato ...

NRx Pharmaceuticals Inc. (NRXP), a pharmaceutical company with a market capitalization of $39.7 million, reported a significant reduction in operational losses and expenses in the fourth quarter ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Width x Height x Depth (without stand) 2025 x 1140 x 90 ...